(Bloomberg) — Biogen Inc. said it plans to resume previous studies of its once-abandoned drug for Alzheimer’s disease, rolling out detailed trial data to a standing-room-only gathering of scientists in California.The company’s in-depth presentation at the Clinical Trials on Alzheimer’s Disease conference in San Diego on Thursday marked a climax in a monthslong saga that has seen patients’ hopes dashed and revived, and Biogen’s stock price plummet and then rebound.It was the first in-depth look Biogen has provided at the experimental treatment, known as aducanumab, since reviving it in October. In March, Biogen declared two studies of the medicine failures …read more
Source:: Yahoo Finance
